Wavefront-guided LASIK for Monovision Treatment of Myopic Subjects With Presbyopia

Launched by AMO DEVELOPMENT, LLC · Aug 29, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at a procedure called wavefront-guided LASIK, which is a type of eye surgery that helps improve vision for people who are both nearsighted (myopic) and experiencing presbyopia, a condition that affects near vision as we age. The goal is to see if this treatment can effectively correct vision in at least 268 participants over a 12-month period. The study is currently recruiting individuals who are at least 40 years old and have certain types of nearsightedness, as well as a need for additional close-up vision correction.

If you're considering participating, you'll need to meet specific criteria, such as having stable vision for at least a year and being able to attend follow-up appointments. Participants can expect to undergo surgery on both eyes, followed by regular check-ups to assess their vision improvement and the success of the treatment. It’s important to note that this study excludes individuals with certain medical conditions, recent eye surgeries, or those who are pregnant or breastfeeding. Overall, this trial aims to provide insights into how effective LASIK surgery can be for people facing these vision challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed informed consent and HIPAA authorization.
• • 2. At least 40 years of age at enrollment (date informed consent signed).
• • 3. The refractive error of both subject's eyes, based on the iDesign refraction selected for treatment ("4.0 mm Rx calc" at 12.5 mm), must be myopic with or without astigmatism up to -6.00 D spherical equivalent (SE), with cylinder up to -3.00 D and minimum pre-operative myopia in their non-dominant eye at least as great as their targeted myopic retention.
• • 4. At least one eye must require a myopic treatment.
• • 5. Anticipated stromal bed thickness of at least 250 microns based on preoperative central corneal pachymetry minus the maximum treatment depth to be ablated (as calculated by the iDesign plus the intended flap thickness).
• • 6. Distance Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better.
• • 7. Require an add power of +1.25 D or more but not greater than +2.00 D at 40 cm.
• • 8. Less than or equal to ±0.50 D difference between cycloplegic and manifest refraction sphere.
• • 9. A stable refractive error (based on a previous exam, medical records, lensometry, or prescription that is at least 12 months prior to the preoperative manifest refraction), as defined by a change of less than or equal to
• • 0.50 D in MRSE (sphere and cylinder).
• 10. Subjects with a history of contact lens wear within the last 4 weeks must discontinue lens wear in order to demonstrate refractive stability according to the following (refractive stability is defined as a change of not more than 0.50 D in manifest refraction sphere and cylinder as well as mean keratometry between measurements): After the Informed Consent process has been completed and subjects are enrolled in the study:
• • Rigid or extended wear contact lenses (toric or spherical) must be removed for at least 3 weeks and soft contact lenses (toric or spherical) for at least 2 weeks prior to the first refraction used to establish stability.
• • After abstaining from contact lens wear for designated time, two consecutive manifest refractions and keratometric readings must be conducted at least 7 days apart
• • I If the subject/eye meets the refractive stability criteria, contact lens wear is not permitted for 2 weeks prior to surgery except as required to test monovision acceptance as described below in the Study Procedures, Contact Lens Trial section NOTE: Refractive stability needs to be confirmed only once during preoperative assessment
• 11. Agreement between manifest refraction (adjusted for optical infinity) and iDesign System refraction chosen for treatment, as follows:
• • Spherical Equivalent: magnitude of the difference is less than 0.625 D.
• • Cylinder: magnitude of the difference is less than or equal to 0.5 D.
• • Cylinder Axis Tolerance: If either the manifest cylinder entered into the iDesign System or the iDesign cylinder selected for treatment is less than 0.5 D, there is no requirement for axis agreement. When both cylinders have a magnitude of at least 0.5 D, the axis tolerance as determined by the iDesign system is linearly reduced from 15 degrees (0.5 D) to 7.5 degrees (7.0 D) based on the average magnitude of both cylinders. Note: If the axis tolerance is not in the calculated range, the iDesign system will produce a warning and this exam may not be used for treatment planning.
• • 12. Willing and capable of complying with follow-up examinations for the duration of the study.
• Exclusion Criteria:
• • 1. Women who are pregnant, breast-feeding, or intend to become pregnant during the study.
• • Note: Women who were pregnant or nursing may not be enrolled until 6 months after either delivery or have stopped nursing and there is documented refractive stability.
• • 2. Concurrent use of systemic (including inhaled) medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment. NOTE: The use of inhaled or systemic corticosteroids, whether chronic or acute, within the past 6 months is deemed to adversely affect healing and subjects using such medications are specifically excluded from eligibility.
• • 3. History of any of the following medical conditions, or any other condition that could affect wound healing: collagen vascular disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or herpes simplex, endocrine disorders (including, but not limited to unstable thyroid disorders and diabetes), lupus, and rheumatoid arthritis.
• • NOTE: The presence of diabetes (either type 1 or 2), regardless of disease duration, severity, or control, will specifically exclude subjects from eligibility.
• • 4. Subjects with a cardiac pacemaker, implanted defibrillator or other implanted electronic device.
• • 5. History of prior intraocular or corneal surgery (including cataract extraction), active ophthalmic disease or abnormality (including, but not limited to, symptomatic blepharitis, recurrent corneal erosion, dry eye syndrome, neovascularization \> 1 mm from limbus), retinal detachment/repair, clinically significant lens opacity, clinical evidence of trauma, corneal opacity within the central 9 mm and visible on topography, prior strabismus surgery, strabismus, or at risk for developing strabismus, or with evidence of glaucoma or propensity for narrow angle glaucoma or suspected glaucoma.
• • NOTE: Subjects with glaucoma, regardless of medication regimen or control, or an IOP greater than 21 mmHg at screening, are specifically excluded from eligibility.
• • 6. Evidence of keratoconus, corneal dystrophy or irregularity, or abnormal topography.
• • 7. Known sensitivity or inappropriate responsiveness to any of the medications used in the postoperative course.
• • 8. Intolerance to monovision correction based on questionnaire responses to contact lens trial (refer to section Study Procedures, Contact Lens Trial below).
• • 9. Concurrent participation in any other clinical trial, or participation in any other clinical trial within the last 14 days.